Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
Related Questions
Would you expect cinacalcet to lower calcium levels in a patient with Familial Hypocalciuric Hypercalcemia (FHH)?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Is there a maximum duration for raloxifene use?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Do you recommend the use of albumin-adjusted calcium measurement formulas to accurately assess calcium levels?
